Johan Faber, PhD, started his career in protein R&D at Novo Nordisk. He spun-out Hemab, jointly from Novo Nordisk and Genmab in 2018, leading the company as CEO through Series A. After this he stepped out to form Cymab to apply the same antibody concept to oncology. Johan is an expert on antibody discovery and development having led multiple programs in both Pharma and biotech, as well as an accomplished biotech leader.